Abstracts presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting explored the adoption of infliximab biosimilars, utilization patterns of bevacizumab biosimilars in ophthalmology and oncology settings, and the budget impact of transferring patients to a natalizumab biosimilar from the originator.
Abstracts presented at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting explored the adoption of infliximab biosimilars, utilization patterns of bevacizumab biosimilars in ophthalmology and oncology settings, and the budget impact of transferring patients to a natalizumab biosimilar from the originator.
Adoption of Infliximab Biosimilars
Regence health plans achieved over 90% adoption of infliximab biosimilars and saved $0.62 per member per month during Q1 2022.1
Medical benefit drug claims for infliximab products were examined from January 2021 to March 2022 for a 1.6 million member commercial payer. The data included biosimilar claim utilization as a percentage all infliximab claims as well as infliximab-related net cost savings. Strategies that were implemented to promote biosimilar adoption consisted of developing messaging about the benefits of biosimilars, coordinated communication with embers and providers, and prior authorization configuration to instill an easy transition.
Utilization of infliximab biosimilars increased from 8% to 94% over 3 years. Initial net savings from using infliximab biosimilars was $2 million over a 3-month post period.
The researchers suggested that having several communication channels between members and providers, a clinically appropriate and thoughtful medical policy, and a prior authorization management plan are critical to achieving early adoption results. Also, longer follow-up and evaluation periods are needed to define long-term strategy savings and success.
Use of Bevacizumab Biosimilars in 2 Fields
Use of bevacizumab biosimilars increased in recent years relative to the originator (Avastin) in the oncology and ophthalmology spaces. Bevacizumab products are indicated for the treatment of several forms of cancer and are often used off-label in the treatment of some retinal conditions.
A retrospective cohort study using data from the Biologics and Biosimilars Collective Intelligence Consortium and assess the utilization patterns of 2 bevacizumab biosimilars (Mvasi, Zirabev) between January 2010 and December 2020.2
Users of bevacizumab were mostly female (61.8%) and had a mean age of 63 years. Patient use of bevacizumab in oncology increased over time, with 5% of the population using a biosimilar. Total bevacizumab product utilization increased for retinal conditions starting in 2015 but decreased for age-related macular degeneration after 2016. Use of biosimilars began to increase in the beginning of 2019 for proliferative diabetic retinopathy.
The researchers noted that there is limited data on the use of bevacizumab biosimilars, and future research should assess the frequency and indication of use for these medications.
Budget Impact of a Natalizumab Biosimilar
Adoption of a natalizumab biosimilar once one becomes available could result in significant cost savings to US health plans, which could be reinvested to increase treatment access to patients with relapsing remitting multiple sclerosis (RRMS), according to one abstract.3
Researchers estimated the 3-year budget impact of transitioning patients with RRMS from originator natalizumab (Tysabri) to a biosimilar version using a hypothetical payer with 1 million members, of whom 265 members were estimated to be treated with high-efficacy disease-modifying therapies for RRMS. The overall cost associated with transitioning to a natalizumab biosimilar was $102,061 in year 1, $156,354 in year 2, $202,804 in year 3. Cost savings per member amounted to $1180 in year 1, $1860 in year 2, and $2508 in year 3.
Reinvesting the generated savings would allow for 5 additional patients with RRMS to receive access to treatment.
References
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.